How To Choose A Contract Sales Organization For A 2027 Launch

By Hoyt Gong

A company launching a drug in the United States in 2027 will hire its contract sales organization (CSO) from a market that has changed since its executives last bought from it. Five of the best-known providers have new owners, new chief executives, or a new reporting structure. Each change is a reason to check who will sign the contract, who will lead the team, and which systems the representatives will use. It also makes two contract terms, named key personnel and change of control, as important as the price.

The record is public. Inizio was assembled in 2022, mostly from the Ashfield and Huntsworth businesses, according to Pharmaceutical Commerce. Syneos Health went private in September 2023, when Elliott Investment Management, Patient Square Capital and Veritas Capital closed their acquisition, a deal announced at about $7.1 billion including debt. EVERSANA merged with Waltz Health in August 2025 and took Waltz's chief executive as its own. Amplity named a new chief executive in April 2026.

IQVIA changed how it reports the business. Its Contract Sales & Medical Solutions unit booked $788 million of revenue in 2025, up 9.7%, according to the company's fourth-quarter earnings release. The same release says that, effective Jan. 1, 2026, the unit was folded into a larger segment renamed Commercial Solutions, so buyers will no longer see its revenue reported on its own.

None of these events predicts how a particular field team will perform. They do mean that the group named on the pitch deck is usually broader than the operating unit that does the work. A launch team that chooses on brand recognition has not yet learned which unit it is hiring.

Write The Role Map Before The Vendor List

Contract sales no longer means only sales representatives. A single request for proposal can now cover representatives, key account managers, field reimbursement managers, nurse educators, inside sales, medical science liaisons, and the patient support work that sits next to them. In July 2026, Citius Oncology said it added 21 commercial field professionals and eight medical science liaisons for its lymphoma drug Lymphir through EVERSANA, which also runs services including medical information, pharmacovigilance, channel management, and patient assistance, according to the company's announcement. A company of that size is buying most of a commercial organization. A large manufacturer filling 40 vacant territories is buying something much narrower, often from the same providers.

Each of those roles works under different rules. A sales representative delivers approved promotional messages. A medical science liaison cannot promote. A field reimbursement manager handles coverage and access questions, and most compliance programs keep that role's pay separate from sales volume. Before comparing providers, write one page per role that states what the person may say, who approves the materials, who supervises the person, how the person is paid, and what result the role is measured on.

The manufacturer stays accountable for outsourced work. Under the FDA's postmarketing rules (21 CFR 314.80), the company that holds the drug's approval must review adverse event information from any source and report serious, unexpected events within 15 calendar days. FDA guidance treats a report received by the company's contractors as received by the company, so a serious side effect that a contract representative hears about in an oncologist's office on a Friday starts that clock. The manufacturer also answers for sample accountability under the Prescription Drug Marketing Act (21 CFR Part 203) and for every promotional piece it files with FDA on Form 2253. The role map has to show how each report travels from the field to the manufacturer's safety and compliance teams, and how fast.

Match The Operating Model To The Launch

Five providers that U.S. launch teams commonly shortlist sell different things. The right starting point depends on what the launch needs, and each one comes with a condition the buyer should prove before award. Global headcount, country counts and group revenue say nothing about the 30 people a provider will put on a given product. Consider the following options and recommended inputs:

• Broad deployment with clinical ties. Syneos Health combines clinical research and commercial services. Prove which commercial unit and which named leaders will run the team.
• Field team plus adjacent services. Inizio Engage sits beside separately run Inizio businesses in patient support, medical, advisory, and communications. Prove which business owns each deliverable, which legal entity signs, and how price and data cross between them.
• One accountable bundle. EVERSANA sells field, hub, pharmacy, market access, agency, and data services together. Price every component separately, benchmark each against a specialist, and keep the right to replace one piece without rebuilding the rest.
• Data-led targeting. IQVIA attaches a field force to the prescription and claims data much of the industry already licenses. Prove how the data changes what a representative does each week, and what the buyer may do with that data after the contract ends.
• A focused team. Amplity and other specialist CSOs sell a bounded field or medical team with less attached to it. That can be easier to govern and to replace. Prove the team's depth in the therapeutic area, and decide who inside the manufacturer will manage the handoffs to the hub, pharmacy, and data vendors.

A sixth option belongs on the list. A manufacturer that expects to own its sales force within two or three years should structure the deal as outsource-to-convert from the start, with the conversion terms agreed at award.

Put Every Bid On The Same Scope

There is no reliable public benchmark for what a contract representative costs or how long a team takes to deploy. Figures that circulate in pitch decks mix different salary bands, incentive plans, vehicles, technology, management ratios, and pass-through costs. A low rate per representative often reflects a smaller scope.

Give every bidder one scope: the same roles, territories, management span, customer relationship management system, training days, and reporting. Then ask for the all-in cost by role and territory, with incentives, travel, technology, minimum commitments, and change-order rates shown separately. Ask what happens to the price if demand forces the team to shrink by a quarter in month nine, and what credit the manufacturer receives while a territory sits vacant.

On speed, ask for the record. Each bidder should report, for its last three comparable deployments, the days from contract signature to the last accepted hire, the vacancy rate at month six and annual turnover. Then call those clients. Interview the national sales director and the first-line managers who will be assigned to the product, because they shape the team more than the executives who attend the pitch.

Test The Handoffs With One Real Case

Specialty launches stall at the handoffs between vendors. A representative learns that a practice's prior authorizations are being denied. The information has to reach the field reimbursement manager, the hub, and sometimes the specialty pharmacy, in a form each is allowed to receive, quickly enough to help the patient.

Hand every finalist the same scenario and ask them to walk it through their actual systems: what gets recorded, in which system, who sees it, how long each step takes, and where patient privacy rules stop the flow. A provider that has run the process will answer with screens and sample reports. One that has not will answer with a platform name. Confirm as well that the manufacturer owns the call history, account notes and territory records, and will receive them in a usable format when the contract ends.

Contract The Exit Before You Sign

The CSO relationship will change. Demand will miss or beat the forecast, payer barriers will shift the mix of roles, or the company will decide to bring the team in house. The terms that govern those changes are cheapest on the day of award, when the provider still wants the business.

Set the conversion fee and timing for hiring representatives directly. Define the bands within which the team can grow or shrink without a penalty. Write down the knowledge transfer duties, the handoff of open accounts, and the transition support owed if the contract ends early.

Finally, add the two clauses reflecting what has happened over the past four years. Name the key personnel, including the national sales director and the account lead, and require the manufacturer's consent to replace them. Add a change-of-control clause that gives the manufacturer a right to exit without penalty if the provider is sold or merged and those people leave. Put both in the first draft of the agreement, because they are hard to add after the award letter goes out.

About The Author:

Hoyt Gong is the founder of Rx Almanac, a research directory of pharmaceutical services vendors, and an MBA candidate at Harvard Business School. His background is in biopharma, technology and strategy.